"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."
This is HCP only content
Terumo Europe NV announces CE Mark approval for FineDuo, a low profile, multifunctional, dual-lumen microcatheter that provides robust support and easy access to complex coronary vasculature.
The FineDuo dual-lumen microcatheter is intended to be used during percutaneous transluminal coronary angioplasty (PTCA) for:
The FineDuo microcatheter allows the operator to deliver a second guidewire through the OTW lumen while leaving the first guidewire in the monorail lumen in place.Kaneka Corporation (headquarters: Osaka; President: Mamoru Kadokura) has signed an OEM agreement with Terumo Corporation (headquarters: Tokyo; President and CEO: Yutaro Shintaku) on dual-lumen microcatheters for European markets. Kaneka will start to supply its dual-lumen microcatheters, named Crusade, to Terumo Corporation, who will sell it as FineDuo. Kaneka will continue to sell it as Crusade dual-lumen microcatheter.Terumo Europe N.V. expects to launch the FineDuo dual-lumen microcatheter in Europe from October 2016.
For further information please contact your Terumo sales representative or visit Terumo booth at the Euro CTO Club (September 30th – October 1st 2016, Poland) and EBC (October 14th – 15th 2016, Rotterdam) congresses or visit the FineDuo webpage.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over $4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in interventional procedures, cardiovascular surgery, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and are a component of the Nikkei, Japan's leading stock index.
Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Cardiovascular Systems, Medical Products and Diabetes Management. Terumo EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA. Please visit www.terumo-europe.com for more information.